??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapy
Authors:
- Karen K. HamiltonKHKaren K. Hamilton
- Daniel F. PaulyDPDaniel F. Pauly
- Craig R. LeeCLCraig R. Lee
- J. Herbert PattersonJPJ. Herbert Patterson
- Kirkwood F. AdamsKAKirkwood F. Adams
- Richard S. SchofieldRSRichard S. Schofield
- Bernadette S. BelgadoBBBernadette S. Belgado
- James A. HillJHJames A. Hill
- Juan M. ArandaJAJuan M. Aranda
- Hossein N. YarandiHYHossein N. Yarandi
- Julie A. JohnsonJJJulie A. Johnson
- 1 April 2005
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 15 (4) , 227-234
Abstract
Large variability exists in the improvement in eft ventricular (LV) function from β-blocker treatment. We hypothesized that polymorphisms at codon 389 (Arg389Gly) and 49 (Ser49Gly) in the β1-adrenergic receptor (AR) gene were associated with LV reverse remodeling changes in response to β-blocker therapy among heart failure patients. We prospectively enrolled 61 β-blocker naïve patients with systolic heart failure. Patients underwent baseline echocardiography followed by metoprolol CR/XL. The dose was doubled on a biweekly basis up to 200 mg/day or attainment of maximum tolerated dose. Echocardiography was repeated after the patient received the target or highest tolerated dose for 3 months. Among patients with the Arg389Arg genotype, ejection fraction (EF) increased from 23±5 to 29±10 (P=0.008). Gly389 carriers did not demonstrate any significant change in EF (22±9 to 23±11; P=0.45). There was a significant between-group difference in EF by genotype (P=0.04). The Arg389Arg genotype was also associated with significantly greater reductions in LV end-diastolic and end-systolic diameters compared to Gly389 carriers. Patients with the Gly49 variant also had a significantly greater reduction in LV end-diastolic diameter compared to Ser49 homozygotes. Multiple regression analysis modeling revealed that the codon 389 polymorphism was a significant predictor of an improvement in EF and both codon 49 and 389 polymorphisms were significant predictors of final LV end-diastolic diameter. Heart failure patients with the Arg389Arg genotype and Gly49 carriers had greater improvements in LV remodeling from β-blocker treatment.Keywords
This publication has 30 references indexed in Scilit:
- Heart FailureNew England Journal of Medicine, 2003
- Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunctionJournal of Cardiac Failure, 2002
- ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summaryJACC, 2001
- Effect of Carvedilol on Survival in Severe Chronic Heart FailureNew England Journal of Medicine, 2001
- Differential Effects of β-Blockers in Patients With Heart FailureCirculation, 2000
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 1999
- Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failureThe American Journal of Cardiology, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Left Ventricular Remodeling With Carvedilol in Patients With Congestive Heart Failure Due to Ischemic Heart Disease fn1fn1This study was funded by a grant from SmithKline Beecham; however, the study was initiated, conducted, analyzed and reported by the Australia–New Zealand Heart Failure Research Collaborative Group independently of the sponsor. The Clinical Trials Research Unit is supported by a programme grant from the Health Research Council of New Zealand.JACC, 1997
- Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockadeJACC, 1995